当前位置: 首页 >> 检索结果
143. Immunogenicity of the 9-Valent HPV Vaccine Using 2-Dose Regimens in Girls and Boys vs a 3-Dose Regimen in Women.
作者: Ole-Erik Iversen.;Maria Jose Miranda.;Angels Ulied.;Terje Soerdal.;Erica Lazarus.;Kulkanya Chokephaibulkit.;Stan L Block.;Ales Skrivanek.;Abdul Ghani Nur Azurah.;Siew Moy Fong.;Vladimir Dvorak.;Kyung-Hyo Kim.;Ramon M Cestero.;Matitiahu Berkovitch.;Mehmet Ceyhan.;Misoo C Ellison.;Michael A Ritter.;Shuai S Yuan.;Mark J DiNubile.;Alfred J Saah.;Alain Luxembourg.
来源: JAMA. 2016年316卷22期2411-2421页
Human papillomavirus (HPV) infections cause anogenital cancers and warts. The 9-valent HPV vaccine provides protection against 7 high-risk types of HPV responsible for 90% of cervical cancers and 2 other HPV types accounting for 90% of genital warts.
145. Prevalence and Prognostic Implications of Coronary Artery Calcification in Low-Risk Women: A Meta-analysis.
作者: Maryam Kavousi.;Chintan S Desai.;Colby Ayers.;Roger S Blumenthal.;Matthew J Budoff.;Amir-Abbas Mahabadi.;M Arfan Ikram.;Aad van der Lugt.;Albert Hofman.;Raimund Erbel.;Amit Khera.;Marie H Geisel.;Karl-Heinz Jöckel.;Nils Lehmann.;Udo Hoffmann.;Christopher J O'Donnell.;Joseph M Massaro.;Kiang Liu.;Stefan Möhlenkamp.;Hongyan Ning.;Oscar H Franco.;Philip Greenland.
来源: JAMA. 2016年316卷20期2126-2134页
The role of coronary artery calcium (CAC) testing for guiding preventive strategies among women at low cardiovascular disease (CVD) risk based on the American College of Cardiology and American Heart Association CVD prevention guidelines is unclear.
146. Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial.
作者: Stephen J Nicholls.;Rishi Puri.;Todd Anderson.;Christie M Ballantyne.;Leslie Cho.;John J P Kastelein.;Wolfgang Koenig.;Ransi Somaratne.;Helina Kassahun.;Jingyuan Yang.;Scott M Wasserman.;Robert Scott.;Imre Ungi.;Jakub Podolec.;Antonius Oude Ophuis.;Jan H Cornel.;Marilyn Borgman.;Danielle M Brennan.;Steven E Nissen.
来源: JAMA. 2016年316卷22期2373-2384页
Reducing levels of low-density lipoprotein cholesterol (LDL-C) with intensive statin therapy reduces progression of coronary atherosclerosis in proportion to achieved LDL-C levels. Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors produce incremental LDL-C lowering in statin-treated patients; however, the effects of these drugs on coronary atherosclerosis have not been evaluated.
154. Statin Use for the Primary Prevention of Cardiovascular Disease in Adults: US Preventive Services Task Force Recommendation Statement.
作者: .;Kirsten Bibbins-Domingo.;David C Grossman.;Susan J Curry.;Karina W Davidson.;John W Epling.;Francisco A R García.;Matthew W Gillman.;Alex R Kemper.;Alex H Krist.;Ann E Kurth.;C Seth Landefeld.;Michael L LeFevre.;Carol M Mangione.;William R Phillips.;Douglas K Owens.;Maureen G Phipps.;Michael P Pignone.
来源: JAMA. 2016年316卷19期1997-2007页
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the United States, accounting for 1 of every 3 deaths among adults.
155. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force.
作者: Roger Chou.;Tracy Dana.;Ian Blazina.;Monica Daeges.;Thomas L Jeanne.
来源: JAMA. 2016年316卷19期2008-2024页
Cardiovascular disease (CVD), the leading cause of mortality and morbidity in the United States, may be potentially preventable with statin therapy.
|